INS and metabolic syndrome: We have previously shown, that in response to an insulin-sensitizing agent given to metabolic syndrome normoglycemic patients, there was a concomitant improvement in skin microvascular dysfunction [15] and in endothelial microvascular reactivity in the muscle [16].